Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 3/20 | 0.32 |
| ▸ | CPT2 | P23786 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28887450 | 1.00 | SCD5 (0.34) | SCD5SCDHSD11B1SRCRIPK1 | |
| SCHEMBL28887421 | 0.84 | RIPK1 (0.35) | RIPK1CPT1AHCRTR1HCRTR2 | |
| SCHEMBL20187368 | 0.84 | RIPK1 (0.35) | RIPK1CPT1AHCRTR1HCRTR2 | |
| SCHEMBL20202187 | 0.77 | AADAT (0.51) | — | |
| SCHEMBL5649137 | 0.71 | RIPK1 (0.42) | SCD5SCDHSD11B1RIPK1CPT1A | |
| SCHEMBL5649142 | 0.71 | RIPK1 (0.42) | SCD5SCDHSD11B1RIPK1CPT1A | |
| SCHEMBL28570568 | 0.70 | SRC (0.35) | SRCRIPK1CPT1A | |
| SCHEMBL28570569 | 0.70 | SRC (0.35) | SRCRIPK1CPT1A | |
| SCHEMBL1769192 | 0.68 | CPT1A (0.45) | CPT1ACPT2 | |
| SCHEMBL20742595 | 0.67 | PRCP (0.37) | SCD5RIPK1CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-110234638-B | Heteroaryl phenoxy benzamide KAPPA opioid ligands | 辉瑞大药厂 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544972-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | Pfizer Inc (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | SCD5 3341/4885SCD 3168/4885HSD11B1 1870/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | SCD5 3341/4885SCD 3168/4885HSD11B1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.